Halozyme Therapeutics, Inc. (HALO) receives a strong valuation score of 75 from InvestorsObserver analysis. Our proprietary scoring system considers the overall health of the company by looking at the stock's price, earnings, and growth rate to determine if it represents a good value. HALO holds a better value than 75% of stocks at its current price. Investors who are focused on long-term growth through buy-and-hold investing will find the Valuation Rank especially relevant when allocating their assets.
HALO currently has a 12-month-forward-PE-to-Growth (PEG) ratio of 0.69. The market is currently undervaluing HALO in relation to its projected growth due to the PEG ratio being below the fair market value of 1. HALO's PEG comes from its forward price to earnings ratio being divided by its growth rate. Because PEG ratios include more fundamentals of a company's overall health with additional focus on the future, they are one of the most used valuation metrics by analysts.
Halozyme Therapeutics, Inc. (HALO) Stock: How Does it Score on Valuation Metrics?
HALO gets a 75 Valuation Rank today. Find out what this means to you and get the rest of the rankings on HALO!